Dupilumab may reduce pruritus and lesion appearance among patients with prurigo nodularis
Prurigo nodularis (PN) is a distressing inflammatory skin condition marked by itchy, reddish lesions.
Dupilumab may reduce pruritus and lesion appearance among patients with prurigo nodularis, according to a comprehensive review of the extensive systemic therapies. The outcomes of the study were published in Journal of Cutaneous Medicine and Surgery.
The primary goal of interventions is to disrupt the destructive itch-scratch cycle associated with Prurigo nodularis, necessitating a multifaceted approach targeting both immune and neural factors. In a recent evidence review, researchers conducted a meticulous search across databases complemented by an exploration of Google Scholar. This resulted in including 88 studies after the elimination of duplicates and irrelevant findings.
Among the different treatments that were scrutinized in this research that identified several promising drugs to solve the inflammatory condition. Dupilumab emerged as a standout by showcasing the efficacy in reducing both pruritus and lesion appearance with notably fewer side effects. Thalidomide and pregabalin also demonstrated effectiveness with concerns over long-term use were also raised due to pain associated with muscle and nerve.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.